Hyperfine Inc (HYPR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Hyperfine Inc stock (HYPR) is currently trading at $1.15. Hyperfine Inc PS ratio (Price-to-Sales) is 8.88. Analyst consensus price target for HYPR is $2.05. WallStSmart rates HYPR as Sell.
- HYPR PE ratio analysis and historical PE chart
- HYPR PS ratio (Price-to-Sales) history and trend
- HYPR intrinsic value — DCF, Graham Number, EPV models
- HYPR stock price prediction 2025 2026 2027 2028 2029 2030
- HYPR fair value vs current price
- HYPR insider transactions and insider buying
- Is HYPR undervalued or overvalued?
- Hyperfine Inc financial analysis — revenue, earnings, cash flow
- HYPR Piotroski F-Score and Altman Z-Score
- HYPR analyst price target and Smart Rating
Hyperfine Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Hyperfine Inc (HYPR) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Hyperfine Inc (HYPR) Key Strengths (1)
Revenue surging 128.00% year-over-year
Supporting Valuation Data
Hyperfine Inc (HYPR) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 8.9x annual revenue
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 4.4x book value
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Hyperfine Inc (HYPR) Detailed Analysis Report
Overall Assessment
This company scores 23/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 1.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 128.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (8.88), Price/Book (4.43) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -79.00%, Operating Margin at -144.90%, Profit Margin at -262.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -79.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 128.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HYPR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HYPR's Price-to-Sales ratio of 8.88x trades at a deep discount to its historical average of 441.57x (37th percentile). The current valuation is 100% below its historical high of 2893.51x set in Feb 2021, and 131% above its historical low of 3.84x in May 2025. Over the past 12 months, the PS ratio has expanded from ~4.6x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Hyperfine Inc (HYPR) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Hyperfine Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 14M with 128% growth year-over-year. The company is currently unprofitable, posting a -262.3% profit margin.
Key Findings
Revenue growing at 128% YoY, reaching 14M. This pace significantly outperforms most MEDICAL DEVICES peers.
Spending 28% of revenue (4M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -262.3% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -5M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Hyperfine Inc maintain 128%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Hyperfine Inc.
Bottom Line
Hyperfine Inc is a high-conviction growth story with revenue accelerating at 128% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -262.3% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Hyperfine Inc(HYPR)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Hyperfine Inc. is a pioneer in medical technology, focusing on transforming access to MRI with innovative point-of-care imaging solutions. As the developer of the first FDA-cleared portable MRI system, the company significantly enhances patient care by delivering high-quality imaging directly at the bedside, which streamlines clinical decision-making. By emphasizing cost efficiency and patient convenience, Hyperfine is strategically positioned to capitalize on the escalating demand for advanced diagnostic imaging solutions in a rapidly changing healthcare environment. Its groundbreaking technology is poised to make a substantial impact on healthcare delivery across various medical settings, representing a promising opportunity for institutional investors.